Evaluating Pharmaceutical Clinical Research Solutions in Latin America

Clinical research in Latin America has grown steadily in recent years. However, sponsors entering the region consider more than just patient volume. Study performance often depends on operational details that only become clear once a trial starts. These include the speed of approvals, the accuracy of enrollment assumptions and the consistency of communication among research teams as timelines tighten.

“i9 Pesquisas Clínicas works in the middle of those day-to-day pressures.”

Many delays occur before the first participant is enrolled. Start-up documents can take time to move between review bodies. Recruitment estimates may weaken as inclusion criteria become more specific. Communication gaps between sponsors, coordinators and investigators can lead to setbacks that affect later phases of a study. As a result, sponsors are paying closer attention to how research organizations manage execution at the site level.

Sponsors usually notice the difference early. Some research sites move studies forward efficiently once activation begins. Others spend weeks going back and forth on documentation, revisions and enrollment assumptions that were never realistic to begin with. A protocol can look solid during feasibility and still slow down later when patient availability turns out to be smaller than expected. Across Latin America, even minor differences in approval pathways or reporting requirements between countries can affect how quickly a study gets underway.

“Study performance often depends on operational details that only become clear once a trial starts.”

Recruitment adds another level of unpredictability. Fields like cardiology, pulmonology, endocrinology, gastroenterology and dermatology may seem to have large patient pools, but eligibility criteria have become much stricter. Sites cannot depend on outreach alone. Enrollment often relies on how well coordinators prescreen patients, how actively physicians engage and whether participants remain committed once the study starts. Research groups with established physician relationships usually find it easier to maintain steady enrollment because the referral process already fosters familiarity and trust.

Study complexity has also changed how sponsors assess research partners. Modern trials generate large amounts of clinical and safety data. Sponsors now expect this information to be documented accurately and reported promptly. Small reporting issues or protocol deviations can become bigger problems later if communication among coordinators, investigators and sponsors is not carefully managed from the beginning.

Brazil’s regulatory landscape has changed as well. Recent reforms aimed at reducing approval delays have made the country more attractive for global clinical programs. Research organizations that adapted early to these changes while keeping stable internal processes are now better positioned to support faster study activation without adding extra operational strain later in the trial.

i9 Pesquisas Clínicas works in the middle of those day-to-day pressures. Operating from Campinas, Brazil, the company supports Phase II, III and IV studies across several therapeutic areas. Its positioning appears to rest less on volume and more on execution discipline, including careful prescreening, continuity across study teams and a low-deviation operating model. A large part of that work comes down to coordination. Recruitment timelines need constant adjustment. Patients require follow-up. Sponsors, investigators and coordinators all need updates at different stages of the study, often simultaneously. i9’s long-tenured team structure is part of that reliability, helping studies move with less operational noise once recruitment and site activity begin. Its structure is built to keep those moving parts aligned while maintaining the reporting and documentation standards sponsors expect during active clinical programs.